Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1980;71(2):473–478. doi: 10.1111/j.1476-5381.1980.tb10960.x

Clonidine distribution in the rat: temporal relationship between tissue levels and blood pressure response.

E L Conway, B Jarrott
PMCID: PMC2044444  PMID: 7470758

Abstract

1. The time course of the distribution of clonidine (20 microgram/kg, i.v.) was determined in the rat by use of a sensitive and specific radioimmunoassay, and was compared with the hypotensive response following this dose. 2. Levels of clonidine were determined in tissues at 2 min, corresponding to the beginning of the hypotensive phase of the drug, and then at 10, 30 and 120 min during recovery of blood pressure to the pre-dose level. The peak tissue concentrations of clonidine were found at 2 min, after which they declined in a mono-exponential manner. The half-lives of clonidine in the various tissues were similar to the half-life of the recovery of blood pressure. 3. Regional variations in clonidine distribution in the brain were not very great; however, the half-life was longer in the corpus striatum and shorter in the cerebellum than in other brain regions. 4. Clonidine concentrations were highest in the kidney and similarly distributed between the cortex and medulla. Concentrations of the drug in other tissues approximated those in brain. 5. Although clonidine is thought to act primarily through the central nervous system, this distribution study shows that at the peak of the hypotensive response less than 2% of the injected dose is present in brain and at least equal concentrations of the drug are found in most peripheral tissues. Thus the possibility of peripheral mechanisms contributing to the hypotensive effect cannot be dismissed.

Full text

PDF
473

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bolme P., Fuxe K. Pharmacological studies on the hypotensive effects of clonidine. Eur J Pharmacol. 1971 Jan;13(2):168–174. doi: 10.1016/0014-2999(71)90147-6. [DOI] [PubMed] [Google Scholar]
  2. Burger H. G., Lee V. W., Rennie G. C. A generalized computer program for the treatment of data from competitive protein-binding assays including radioimmunoassays. J Lab Clin Med. 1972 Aug;80(2):302–312. [PubMed] [Google Scholar]
  3. Cho A. K., Curry S. H. The physiological disposition of 2(2,6-dichloroanilino)-2-imidazoline (St-155). Biochem Pharmacol. 1969 Feb;18(2):511–520. doi: 10.1016/0006-2952(69)90227-5. [DOI] [PubMed] [Google Scholar]
  4. Glowinski J., Iversen L. L. Regional studies of catecholamines in the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain. J Neurochem. 1966 Aug;13(8):655–669. doi: 10.1111/j.1471-4159.1966.tb09873.x. [DOI] [PubMed] [Google Scholar]
  5. Horn A. S., Cuello A. C., Miller R. J. Dopamine in the mesolimbic system of the rat brain: endogenous levels and the effects of drugs on the uptake mechanism and stimulation of adenylate cyclase activity. J Neurochem. 1974 Feb;22(2):265–270. doi: 10.1111/j.1471-4159.1974.tb11589.x. [DOI] [PubMed] [Google Scholar]
  6. Jarrott B., Spector S. Disposition of clonidine in rats as determined by radioimmunoassay. J Pharmacol Exp Ther. 1978 Oct;207(1):195–202. [PubMed] [Google Scholar]
  7. Kobinger Central alpha-adrenergic systems as targets for hypotensive drugs. Rev Physiol Biochem Pharmacol. 1978;81:39–100. doi: 10.1007/BFb0034091. [DOI] [PubMed] [Google Scholar]
  8. Rehbinder D., Deckers W. Untersuchungen zur Pharmakokinetik und zum Metabolismus des 2-(2,6-Dichlorphenylamino)-2-imidazolin-hydrochlorid (St 155) Arzneimittelforschung. 1969 Feb;19(2):169–176. [PubMed] [Google Scholar]
  9. Schmitt H., Fenard S. Evidence for an alpha-sympathomimetic component in the effects of catapresan on vasomotor centres: antagonism by piperoxane. Eur J Pharmacol. 1971;14(1):98–100. doi: 10.1016/0014-2999(71)90130-0. [DOI] [PubMed] [Google Scholar]
  10. Timmermans P. B., Brands A., van Zwieten P. A. Lipophilicity and brain disposition of clonidine and structurally related imidazolidines. Naunyn Schmiedebergs Arch Pharmacol. 1977 Nov;300(3):217–226. doi: 10.1007/BF00500963. [DOI] [PubMed] [Google Scholar]
  11. Timmermans P. B., Van Zwieten P. A. Central and peripheral alpha-adrenergic effects of some imidazolidines. Eur J Pharmacol. 1977 Oct 1;45(3):229–236. doi: 10.1016/0014-2999(77)90003-6. [DOI] [PubMed] [Google Scholar]
  12. U'Prichard D. C., Bechtel W. D., Rouot B. M., Snyder S. H. Multiple apparent alpha-noradrenergic receptor binding sites in rat brain: effect of 6-hydroxydopamine. Mol Pharmacol. 1979 Jul;16(1):47–60. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES